Updated phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in sickle cell disease.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Advertisement
MDS Roundtables
Expert Interviews on Hematology
Conference Coverage
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
The editors of Heme Today review major presentations on classical hematology from the 2023 ASH Annual Meeting & ...
